Plasmacytic differentiation in MALT lymphomas following treatment with rituximab

Annals of Hematology

Volumn 91, Issue 5, 2012, Pages 723-728

  Troch, Marlene ^a   Kiesewetter, Barbara ^a   Dolak, Werner ^a   Jaeger, Ulrich ^a   Püspök, Andreas ^a   Müllauer, Leonhard ^a   Chott, Andreas ^a,b   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Wilheminenspital ^*  (Austria)

Author keywords

MALT lymphoma; Monoclonal gammopathy; Plasmacytic differentiation; Rituximab

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN M; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; PLASMA CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; FOLLOW UP; IMMUNOPHENOTYPING; MARGINAL ZONE LYMPHOMA; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM STAGING; PLASMA CELLS; RETROSPECTIVE STUDIES;

EID: 84861433461     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1387-9     Document Type: Article

References (22)

1. Isaacson PG (1999) Gastric MALT-lymphoma: from concept to cure. Ann Oncol 10(6):637-645
2. Isaacson P, Wright DH (1983) Malignant lymphoma of mucosaassociated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52:1410-1416
3. Wöhrer S, Troch M, Streubel B et al (2007) Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. Ann Oncol 18(12):2020-2024 (Pubitemid 350286243)
4. Van Huyen JP, Molina T, Delmer A et al (2000) Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol 24(12):1581-1592
5. HoffmannM, Wöhrer S, Becherer A, Chott A, Streubel B, Kletter K, Raderer M (2006) 18 F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol 17(12):1761-1765 (Pubitemid 44884049)
6. Stathis A, Chini C, Bertoni F et al (2009) Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastricmarginal zone B-cell lymphoma of MALT type. Ann Oncol 20:1086-1093
7. Hancock BW, QianW, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E (2009) Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 144(3):367-375
8. Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M (2009) A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 94 (5):738-742
9. Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C (2009) Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 115(22):5210-5217
10. Martinelli G, Laszlo D, Ferreri AJ et al (2005) Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23:1979-1983 (Pubitemid 46211377)
11. Raderer M, Jäger G, Brugger S, Püspök A, Fiebiger W, Drach J, Wotherspoon A, Chott A (2003) Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosaassociated lymphoid tissue lymphoma. Oncology 65(4):306-310 (Pubitemid 38064941)
12. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumors of haematopoietic and lymphod tissues, 4th edn. IARC, Lyon
13. Raderer M, Wöhrer S, Streubel B, Troch M, Turetschek K, Jäger U, Skrabs C, Gaiger A, Drach J, Puespoek A, Formanek M, Hoffmann M, Hauff W, Chott A (2006) Assessment of disease dissemination in gastric compared with extragastric mucosaassociated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 24(19):3136-3141 (Pubitemid 46646224)
14. Copie-Bergman C, Gaulard P, Lavergne-Slove A et al (2003) Proposal for a new histological grading system for posttreatment evaluation of gastric MALT lymphoma. Gut 52:1656 (Pubitemid 37363454)
15. Zucca E, Bertoni F, Roggero E, Cavalli F (2000) The gastric marginal B-cell lymphoma of MALT type. Blood 96(2):410-419 (Pubitemid 30463357)
16. Wündisch T, Thiede C, Morgner A et al (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23(31):8018-8024 (Pubitemid 46657403)
17. Ruskone-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, Montalban C, Raderer M, Savio A, Wotherspoon A; on behalf of the EGILS group (2011). EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60(6):747-758
18. Aviles A, Nambo MJ, Neri N, Talavera A, Cleto S (2005) Mucosa associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled trial. Med Oncol 22(1):57-62 (Pubitemid 40647230)
19. Woehrer S, Streubel B, Chott A et al (2005) Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma 46 (11):1645-1649 (Pubitemid 41700999)
20. Hoffmann M, Troch M, Eidherr H, Traub-Weidinger T, Jonak C, Muellauer L, Raderer M (2011) 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma 52(1):42-45
21. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW (2009) Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20(4):709-714
22. Orciuolo E, Buda G, Sordi E et al (2009) 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 34(2):184-189